Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

Current Topics in Medicinal Chemistry

Volumn 5, Issue 2, 2005, Pages 215-229

  Wallace, Eli M ^a   Lyssikatos, Joseph P ^a   Yeh, Tammie ^a   Winkler, James D ^a   Koch, Kevin ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

ARRY 142886 (AZD 6244); Cancer; CI 1040; ERK; Kinase inhibitor; MAP kinase; MEK inhibitor; PD 0325901

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 10 HYMENIALDISINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 BROMO N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOPHENYLAMINO) BENZAMIDE; ADENOSINE TRIPHOSPHATE; ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; ARRY 142886; AZD 6244; BENZAMIDE DERIVATIVE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; L 779450; L 783277; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODO PHENYLAMINO) BENZAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PD 0318088; PROTEIN KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RAF PROTEIN; RAS PROTEIN; RO 09 2210; SKF 108752; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COMPETITIVE INHIBITION; DIARRHEA; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HUMAN; LUNG CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; NONHUMAN; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; RASH; REVIEW; THYROID PAPILLARY CARCINOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 17144418558     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053507723     Document Type: Review

References (77)

1. Johnson G.L.; Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911-1912.
2. Hilger R.A.; Scheulen M.E.; Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002, 6, 511-518.
3. Chang F.; Steelman L.S.; Lee J.T.; Shelton J.G.; Navolanic P.M.; Blalock W.L.; Franklin R.A.; McCubrey J.A. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17(7), 1263-1293.
4. Sebolt-Leopold J.S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Des. 2004, 10(16), 1907-1914.
5. Ahn, N.G.; Nahreini, T.S.; Tolwinski, N.S.; Resing, K.A. Pharmacologic inhibitors of MKK1 and MKK2. Meth. Enzymol. 2001 332, 417-431.
6. (a) Khokhlatchev, A.V.; Canagarajah, B.; Wilsbacher, J.; Robinson, M.; Atkinson, M.; Goldsmith, E.; Cobb: M.H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 1998, 93, 605-615.
7. (b) Lewis, T.S.; Hunt, J.B.; Aveline, L.D.; Jonscher, K.R.; Louie, D.F.; Yeh, J.M.; Nahreini, T.S.; Resing, K.A.; Ahn, N.G. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol. Cell 2000, 6, 1343-1354.
8. Hoshino, R.; Chantani, Y.; Yamori, T.; Tsuruo, T.; Oka, H.; Yoshida, O.; Shimada, Y.; Ari-I, S.; Wada, H.; Fujimoto, J.; Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18, 813-822.
9. Bos, J.L. Ras oncogenes in human cancer: a review. Cancer Res. 1989, 49(17), 4682-4689.
10. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892), 949-954.
11. (b) Cohen, Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu, G.; Trink, B.; Beller, U.; Westra, W.H.; Ladenson, P.W.; Sidransky, D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95(8), 625-627.
12. (c) Xu, X.; Quiros, R.M.; Gattuso, P.; Ain, K.B.; Prinz, R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003, 63(15), 4561-4567.
13. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19(13), 3159-3167.
14. Krepinsky, J.; Wu, D.; Ingram, A.; Scholey, J.; Tang, D. Development in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease. Expert Opin. Ther. Patents 2002, 12, 1795-1811.
15. Duan, W.; Chan, J.H.; Wong, C.H.; Leung, B.P.; Wong, W.S. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J. Immunol. 2004, 172, 7053-7059.
16. Pelletier, J.P.; Fernandes, J.C.; Brunet, J.; Moldovan, F.; Schrier, D.; Flory, C.; Martel-Pelletier, J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003, 48, 1582-1593.
17. Ciruela, A.; Dixon, A.K.; Bramwell, S.; Gonzalez, M.I.; Pinnock, R.D.; Lee, K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003, 138 751-756.
18. Ludwig, S.; Wolff, T.; Ehrhardt, C.; Wurzer, W.J.; Reinhardt, J.; Planz, O.; Pleschka, S. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 2004, 12;561, 37-43.
19. Harries, M.; Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002, 9 2), 75-85.
20. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur. R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8(4), 303-306.
21. Grunwald, V.; Hidalgo, M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv. Exp. Med. Biol. 2003, 532, 235-246.
22. Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3(5), 391-400.
23. Caponigro, F.; Casale, M.; Bryce, J. Farnesyl transferase inhibitors in clinical development. Expert Opin. Investig. Drugs. 2003, 12(6), 943-954.
24. Fu, H.W.; Casey, P.J. Enzymology and biology of CaaX protein prenylation. Recent Prog. Horm. Res. 1999, 54, 315-342, discussion 342-343.
25. Chiu, V.K.; Silletti, J.; Dinsell, V.; Wiener, H.; Loukeris, K.; Ou, G.; Philips, M.R.; Pillinger, M.H. Carboxyl methylation of Ras regulates membrane targeting and effector engagement. J. Biol Chem. 2004, 279(8), 7346-7352.
26. Wilhelm, S.; Chien, D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 2002, 8(25), 2255-2257.
27. Ratain, M.J.; Flaherty, K.T.; Stadler, W.M.; O'Dwyer, P.; Kaye, S.; Xiong, H.; Patnaik, A.; Gore, M.; Lee, R.J.; Eisen, T. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 2004, 22(14S), 4501.
28. Giroux, S.; Tremblay, M.; Bernard, D.;Cardin-Girard, J.F.; Aubry, S.; Larouche, L.; Rousseau, S.; Huot, J.; Landry, J.; Jeannotte, L.; Charron, J. Embryonic death of MEK1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 1999, 9(7), 369-372.
29. Belanger, L.F.; Roy, S.; Tremblay, M.; Brott, B.; Steff, A.M.; Mourad, W.; Hugo, P.; Erikson, R.; Charron, J. MEK2 is dispensable for mouse growth and development. Mol. Cell Biol. 2003, 23 14), 4778-4787.
30. Array BioPharma unpublished data.
31. Zhang, N.; Wu, B.; Powell, D.; Wissner, A.; Floyd, M. B.; Kovacs, E. D.; Toral-Barza, L.; Kohler, C. Synthesis and Structure-Activity Relationships of 3-Cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) Inhibitors. Bioorg. Med. Chem. 2000, 10, 2825-2828.
32. Zhang, N.; Wu, B.; Eudy, N.; Wang, Y.; Fei, Yu.; Powell, D.; Wissner, A.; Feldberg, L. R.; Kim, S. C.; Mallon, R.; Kovacs, E. D.; Toral-Barza, L.; Kohler, C. MEK (MAPKK) Inhibitors. Part 2: Structure-Activity Relationships of 4-Anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg. Med. Chem. 2001, 11, 1407-1410.
33. Zhang, N.; Wu, B.; Wissner, A.; Powell, D.; Rabindran, S. K.; Kohler, C.; Boschelli, F. 4-Anilino-3-cyanobenzo[g]quinolines as Kinase Inhibitors. Bioorg. Med. Chem. 2002, 12, 423-425.
34. Berger, D.; Dutia, M.; Powell, D.; Wu, B.; Wissner, A.; Boschelli, D. H.; Floyd, B. M.; Zhang, N.; Torres, N.; Levin, J.; Du, X.; Wojciechowicz, D.; Discafani, C.; Kohler, C.; Kim, S. C.; Feldberg, L. R.; Collins, K.; Mallon, R. Synthesis and Evaluation of 4-Anilino-6, 7-dialkoxy-3-quinolinecarbonitriles as Inhibitors of Kinases of the Ras-MAPK Signaling Cascade. Bioorg. Med. Chem. 2003, 13 3031-3034.
35. Mallon, R.; Feldberg, L.; Kim, S.; Collins, K.; Wojciechowicz, D.; Kohler, C.; Kovacs, D.; Discafani, C.; Zhang, N.; Wu, B.; Floyd, B.; Powell, D.; Berger, D. Identification of 4-Anilino-3-quinoline-carbonitrile Inhibitors of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase 1 Kinase. Molecular Cancer Therapeutics 2004, 3(6), 755-762.
36. (a) Berger, D. M.; Dutia, M.; Powell, D. W.; Tores, N.; Wu, B.; Wissner, A.; Zhang, N.; Levin, J. I.; Du, X.; Mallon, R.; Wojciechowicz, D.; Kohler, C. Synthesis and Evaluation of 4-Anilino Substituted 3-Quninolinecarbonitriles as Inhibitors of Kinases of the Ras-MAPK Signalng Cacsade. ACS Meeting. 2002, 224th Boston (MEDI-105).
37. (b) Dutia, M.; Berger, D. M.; Powell, D. W.; Tores, N.; Wu, B.; Honores, E.; Levin, J. I.; Du, X.; Floyd, M. B.; Wissner, A.; Boschelli, D. H.; et al Synthesis and Evaluation of 4-Anilino Substituted 3-Quninolinecarbonitriles as Inhibitors of Kinases of the Ras-MAPK Signalng Cacsade. ACS Meeting 2002, 224th:Boston (MEDI-104).
38. Abrous, L.; Dutia, M.; Powell, D. W.; Berger, D. M.; Collins, K.; Wojciechowicz, D.; Mallon, R. The Effect of the Linker Group and Heteroatom Modification on a Series of Quinoline-3-Carbonitrile MEK inhibitors: An SAR Study. ACS Meeting 2004, 228th, Philadelphia (MEDI-221).
39. Berger, D. M.; Cole, D.; Dutia, M.; Honore, E., Powell, D. W.; Feldberg, L.; Wojciechowicz, D.; Mallom, R. 7-Aryl Substituted-4-Anilinoquinoline-3-Carbonitrile as Potent MEK-1 Kinase Inhibitors. ACS Meeting 2004, 228th:Philadelphia (MEDI-220).
40. (a) Zhang, N.; Wu, B.; Powell, D.; Wissner, A.; Toral-Barza, L.; Kovacs, E. D.; Kohler, C. Inhibitors of the MEK/ERK MAP Kinase Pathways as Anti-Tumor Agents. Frontiers of Biotechnology & Pharmaceuticals. 2000, 1, 305-312;
41. (b) Berger, D. M.; Mallon., R. Kinase Components of the Ras-MAPK Signaling Cascade as Potential Targets as Potential Targets for Therapeutic Intervention. Drugs of the Future 2003, 28(12) 1211-1226.
42. (a) Huang, C. Y.; Ferrell, J. E.; UltRasensitivity in the Mitogen-Activated Protein Kinase Cascade. Proc. Natl. Acad. Sci. USA 1996, 93, 10078-10083;
43. (b) Burack, W. R.; Sturgill, T. W.; The Activating Dual Phosphorylation of MAPK by MEK is Nonprocessive. Biochemistry 1997, 36, 5929-5933.
44. Methylenediozyanilinoquinazolines and Cyanoquinolines as Inhibitors of MEK and/or Src. Expert. Opin. Ther. Patents 2004 14(7), 1095-1100.
45. Williams, D. H.; Wilkinson, S. E.; Purton, T.; Lamont, A.; Flotow, H.; Murray, E. J. Ro 09-2210 Exhibits Potent Anti-Proliferative Effects on Activated T-Cells by Selectively Blocking MKK Activity. Biochemistry 1998, 37, 9579-9585.
46. Zhao, A.; Lee, S. H.; Mojena, M.; Jenkins, R. G.; Patrick, D. R.; Huber, H. E.; Goetz, M. A.; Hensens, O. D.; Zink, D. L.; Vilella, D.; Dombrowski, A. W.; Lingham, R. B. Resorcyclic Acid Lactones: Naturally Occurring Potent and Selective Inhibitors of MEK. J. Antibiot. 1999, 52(12), 1086-1094.
47. Tasdemir, D.; Mallon, R.; Greenstein, M.; Feldberg, L. R.; Kim, S. C.; Collins, K.; Wojciechowicz, D.; Mangalindan, G. C.; Concepcion, G. P.; Harper, M. K.; Ireland, C. M. Aldisine Alkaloids form the Phillipine Sponge Stylissa massa Are Potent Inhibitors of Mitogen-Actuvated Protein Kinase-Kinase-1 (MEK-1). J. Med. Chem. 2002, 45, 529-532.
48. Meijer, L.; Thunnissen, A.-M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L.-H. Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E-M.; Kim, S.-H.; Petit, G. R. Inhibition of Cyclin-Dependent Kinases, GSK-3β and CK1 by Hymenialdisine, a Marine Sponge Constituent. Chemistry & Biology 2000, 7, 51-63.
49. Badger, A. M.; Cook, M. N.; Swift, B. A.; Newmann-Tarr, T. M.; Gowen, M.; Lark, M. Inhibition of Interleukin-1-Induced Proteoglycan Degradation and Nitric Oxide Production in Bovine Articular Cartilage/Chondrocyte Cultures by the Natural Product, Hymenialdisine. J. Pharmacol. Exp. Ther. 1999, 290, 587-593.
50. Sharma, V.; Lansdell, T.; Jin, G.; Tepe, J. J. Inhibition of Cytokine Production by Hymenialdisine Derivatives. J. Med. Chem. 2004, 47, 3700-3703.
51. Sharma, V.; Tepe, J. J. Potent Inhibition of Checkpoint Kinase Activity by a Hymenialdisine-Derived Indoloazepine. Bioorg. Med. Chem. 2004, 14, 4319-4321.
52. Wan, Y.; Hur, W.; Cho, C. Y.; Liu, Y.; Adrian, F. J.; Lozach, O.; Bach, S.; Mayer, T.; Fabbro, D.; Meijer, L.; Gray, N. S. Synthesis and Target Identification of Hymenialdisine Analogs. Chemistry & Biology 2004, 11, 247-259.
53. (a) Dudley, D.T.; Pang, L.; Decker, S.J.; Bridges, A.J.; Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Nat. Acad. Sci., USA 1995, 92, 7686-7689.
54. (b) Alessi, D.R.; Cuenda, A.; Cohen, P.; Dudley, D.T.; Saltiel, A.R. PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in vitro and in vivo. J. Biol. Chem. 1995, 270, 27489-27494.
55. (a) Favata, M.F.; Horiuchi, K.Y.; Manos, E.J.; Daulerio, A.J.; Stradley, D.A.; Feeser, W.S.; Van Dyk, D.E.; Pitts, W.J.; Earl, R.A.; Hobbs, F.; Copeland, R.A.; Magolda, R.L.; Scherle, P.A.; Trzaskos, J.M. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase. J. Biol. Chem. 1998, 272(29), 18623-18632.
56. (b) Duncia, J.V.; Santella III, J.B.; Higley, C.A.; Pitts, W.J.; Wityak, J.; Frietze, W.E.; Rankin, F.W.; Sun, J-H.; Earl, R.A.; Tabaka, A.C.; Teleha, C.A.; Blom, K.F.; Favata, M.F.; Manos, E.J.; Daulerio, A.J.; Stradley, D.A.; Horiuchi, K.; Copeland, R.A.; Scherle, P.A.; Trzaskos, J.M.; Magolda, R.L.; Trainor, G.L.; Wexler, R.R.; Hobbs, F.W.; Olson, R.E. MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products. Bioorg. Med. Chem. Lett. 1998, 8, 2839-2844.
57. Wityak, J.; Hobbs, F.W.; Gardner, D.S.; Santella III, J.B.; Petraitis, J.J.; Sun, J-H.; Favata, M.F.; Daulerio, A.J.; Horiuchi, K.Y.; Copeland, R.A.; Scherle, P.A.; Jaffe, B.D.; Trzaskos, J.M.; Magolda, R.L.; Trainor, G.L.; Duncia, J.V. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of Potent MEK inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1483-1486.
58. Sebolt-Leopold, J.S.; Dudley, D.T.; Herrera, R.; Van Becelaere, K.; Wiland, A.; Gowan, R.C.; Tecle, H.; Barrett, S.D.; Bridges, A.; Przybranowski, S.; Leopold, W.R.; Saltiel, A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5, 810-816.
59. Tecle, H. The Development of Kinase Inhibitors with Unusual Mechanism of Action: CI-1040, A Selective, Non-ATP Competitive MEK Inhibitor in the Clinic. IBC 2nd International Conference Protein Kinases: Target Validation, Drug Discovery and Clinical Development of Kinase Therapeutics 2002, September 9-10.
60. Dumas, J. Exp. Opin. Ther. Patents 2001, 11 3), 405-429.
61. (a) Sebolt-Leopold, J.S. Oncogene 2000, 19, 6594-6599.
62. (b) Allen, L.F.; Sebolt-Leopold, J.; Meyer, M.B. CI-1040 (PD184352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK). Semin. Oncol. 2003, 30(5, Suppl 16), 105-116.
63. Tecle, H. The Development of Non-ATP Competitive MEK Inhbitors as Potential Anticancer Drugs. The 29th Medicinal Chemistry Symposium 2004, June 27-July 1.
64. Kaufman, M.D.; Barrett, S.D.; Flamme, C.M.; Warmus, J. Smith, Y.D.; Cheriyan, M.; Zhang, L.; Tecle, H.; Sebolt-Leopold, J.; Valik, H.; Gowan, R.; Van Becelaere, K.; Merriman, R.; Przybranowski, S.; Ohren, J.; Whitehead, C.; Leopold, W.R.; Dobrusin, E.; Bridges, A. Synthesis and SAR Development of PD 0325901, a Potent and Highly Bioavailable MEK Inhibitor. Proc. Am. Assoc. Cancer Res. 2004, 45, Abst. 2477.
65. Brown, A.P.; Carlson, T.; Loi, C-M.; Graziano, M.J. Pharmacological Inhibition of the MEK-MAP Kinase Signal Transduction Pathway in the Rat. Proc. Am. Assoc. Cancer Res. 2004, 45 Abst. 2124.
66. Sebolt-Leopold, J.S., Merriman, R., Klohs, W., Meyer, M., Tecle, H. Whitehead, C., Ohren, J., Loi, C-M., Leopold, W.R. Highly Selective Kinase Inhibitors: Too Much of a Good Thing? Proc 15th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2003, 15, 248.
67. (a) Yeh, T.; Wallace, E.; Marsh, V.; Bernat, B.; Gross, S.; Evans, R.; Colwell, H.; Parry, J.; Baker, S.; Ballard, J.; Morales, T.; Smith, D.; Brandhuber, B.; Lyssikatos, J.; Winkler, J. ARRY-142886, A Potent and Selective MEK Inhibitor: I) ATP-Independent Inhibition Results in High Enzymatic and Cellular Selectivity. Proc. Am. Assoc. Cancer Res. 2004, 45, Abst. 3888.
68. (b) Yeh, T.; Wallace. E.; Lyssikatos, J.; Winkler, J. ARRY-142886, A Potent and Selective MEK Inhibitor: II) Potency Against Cellular MEK Leads to Inhibition of Cellular Proliferation and Induction in Apoptosis in Cell Lines with Mutant Ras or B-Raf. Proc. Am. Assoc. Cancer Res. 2004, 45, Abst. 3889.
69. (c) Lee, P.; Wallace, E.; Yeh, T.; Poch, G.; Litwiler, K.; Pheneger, T.; Lyssikatos, J.; Winker, J. ARRY-142886, A Potent and Selective MEK Inhibitor: III) Efficacy against human xenograft models correlates with decreased ERK phosphorylation. Proc. Am. Assoc. Cancer Res. 2004, 45, Abst. 3890.
70. (d) Wallace, E.; Yeh, T.; Lyssikatos, J.; Winkler, J.; Lee, P.; Marlow, A.; Hurley, B.; Marsh, V.; Bernat, B.; Evans, R.; Colwell, H.; Parry, J.; Baker, S.; Ballard, J.; Morales, T.; Smith, D.; Brandhuber, B.; Gross, S.; Poch, G.; Litwiler, K.; Hingorani, G.; Otten, J.; Sullivan, F.; Blake, J.; Rizzi, J.; Pheneger, T.; Goyette, M.; Koch, K. Preclinical Development of ARRY-142886, A Potent and Selective MEK Inhibitor. Proc. Am. Assoc. Cancer Res. 2004, 45, Abst. 3891.
71. Winkler, J.D.; Lee, P.A.; Wallace, E.; Poch, G.; Litwiler, K.; Pheneger, T.; Lyssikatos, J.; Perrier, M.; Eckhardt, S.G.; Yeh, T.C. Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model. Proc 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2004, 16, Abst. 342.
72. (a) Chen, H.; Delaney, A.M.; Dudley, D.T.; Hasemann, C.A.; Kuffa, P.; McConnell, P.C.; Ohren, J.F.; Pavlovsky, A.G.; Tecle, H.; Whitehead, C.E.; Yan, C.; Zhang, E. Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof. Pfizer Limited; EP1321518, 2002.
73. (b) Dudley, D.T. Development of Non-ATP Competitive MEK1 Inhibitors. CHI's 2nd Annual Protein Kinase Targets: Strategies for Drug Development 2004, June 9-10.
74. Lorusso, P.M.; Adjei AA, Meyer MB, Wozniak A, Gadgeel SM, Hanson LJ, Reid JM, Mitchel DY, Bruzek LM, Leopold JS, Herrera R, et al. A Phase I clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, Abst. 321.
75. Mitchell, D.Y.; Reid, J.M.; Parchment, R.E.; Meyer, M.B.; Leopold, J.S.; Herrera, R.; Piens, R.; Bruzek, L.M.; Hanson, L.J.; Van Becelaere, K.; Carlson, T. et al. Pharmacokinetics (PK) and pharmacodynamic (PD) of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, Abst. 320.
76. (a) Waterhouse, D.M.; Rinchart, J.; Adjei, A.A.; Hecht, J.R.; Batale, R.B.; Lorusso, P.M.; Asbury, P.C.; Hamid, O.; Gulyas, S.; Meyer, M.B. A phase 2 study of an oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, or pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2003, 22, Abst. 816.
77. (b) Rinehart, J.; Adjei, A.A.; LoRusso, P.M.; Waterhouse, D.; Hecht, J.R.; Natale, R.B.; Hamid, O.; Varterasian, M.; Asbury, P.; Kaldjian, E.P.; Gulyas, S.; Mitchell, D.Y.; Herrera, R.; Seobolt-Leopold, J.S.; Meyer, M.B. Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer. J. Clin. Oncol. 2004, 22, 4456-4462.